Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dacomitinib

FDA-approved product (tablet, oral), marketed as Vizimpro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dacomitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dacomitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dacomitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

    NCT01484847 · start 2011-12

    Registered record
    Registry ID
    NCT01484847
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-12
    Completion
    2015-07
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionPF-00299804
    PhaseNot applicable
    Registry statusCompleted

  • PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

    NCT01449201 · start 2011-10

    Registered record
    Registry ID
    NCT01449201
    Conditions
    Head Neck Cancer Squamous Cell Metastatic; Head Neck Cancer Squamous Cell Recurrent
    Interventions
    PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2014-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead Neck Cancer Squamous Cell Metastatic; Head Neck Cancer Squamous Cell Recurrent
    InterventionPF-00299804
    PhasePhase 2
    Registry statusCompleted

  • -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

    NCT01441128 · start 2011-09-01

    Registered record
    Registry ID
    NCT01441128
    Conditions
    Carcinoma, Non-Small Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Large Cell
    Interventions
    PF-02341066/PF-00299804; PF-02341066/PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-09-01
    Completion
    2015-02-26
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Large Cell
    InterventionPF-02341066/PF-00299804; PF-02341066/PF-00299804
    PhasePhase 1
    Registry statusTerminated

  • ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

    NCT01360554 · start 2011-06-16

    Registered record
    Registry ID
    NCT01360554
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Dacomitinib (PF-00299804); Active Comparator (erlotinib); Placebo erlotinib; Placebo PF00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-06-16
    Completion
    2015-09-14
    Enrolment
    878

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionDacomitinib (PF-00299804); Active Comparator (erlotinib); Placebo erlotinib; Placebo PF00299804
    PhasePhase 3
    Registry statusCompleted

  • A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804

    NCT01313793 · start 2011-04

    Registered record
    Registry ID
    NCT01313793
    Conditions
    Healthy Volunteers
    Interventions
    Treatment A-B; Treatment B-A
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-05
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTreatment A-B; Treatment B-A
    PhasePhase 1
    Registry statusCompleted

  • Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects

    NCT01318031 · start 2011-03

    Registered record
    Registry ID
    NCT01318031
    Conditions
    Healthy Volunteers
    Interventions
    Period 1; Period 2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-06
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPeriod 1; Period 2
    PhasePhase 1
    Registry statusCompleted

  • A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

    NCT01121575 · start 2010-08

    Registered record
    Registry ID
    NCT01121575
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    PF-02341066; PF-00299804; PF-02341066; PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2014-02
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionPF-02341066; PF-00299804; PF-02341066; PF-00299804
    PhasePhase 1
    Registry statusCompleted

  • PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer

    NCT01152853 · start 2010-07

    Registered record
    Registry ID
    NCT01152853
    Conditions
    Advanced Gastric Cancer; HER2
    Interventions
    PF00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    2012-09
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Gastric Cancer; HER2
    InterventionPF00299804
    PhasePhase 2
    Registry statusCompleted

  • Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

    NCT01116843 · start 2010-05

    Registered record
    Registry ID
    NCT01116843
    Conditions
    Oral Cavity Cancer
    Interventions
    PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2014-02
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Cavity Cancer
    InterventionPF-00299804
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers

    NCT01034748 · start 2010-01

    Registered record
    Registry ID
    NCT01034748
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    [14C]PF00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    Intervention[14C]PF00299804
    PhasePhase 1
    Registry statusCompleted

  • PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

    NCT01000025 · start 2009-12-23

    Registered record
    Registry ID
    NCT01000025
    Conditions
    Lung Cancer
    Interventions
    PF-00299804; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12-23
    Completion
    2015-11-27
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionPF-00299804; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers

    NCT00999817 · start 2009-11

    Registered record
    Registry ID
    NCT00999817
    Conditions
    Healthy Volunteers
    Interventions
    reference [dextromethorphan]; test [PF-00299804 + dextromethorphan]
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2009-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventionreference [dextromethorphan]; test [PF-00299804 + dextromethorphan]
    PhasePhase 1
    Registry statusCompleted

  • Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

    NCT00818441 · start 2009-03-11

    Registered record
    Registry ID
    NCT00818441
    Conditions
    Carcinoma, Non-small Cell
    Interventions
    Dacomitinib (PF-00299804); Dacomitinib (PF-00299804)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03-11
    Completion
    2015-04-30
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-small Cell
    InterventionDacomitinib (PF-00299804); Dacomitinib (PF-00299804)
    PhasePhase 2
    Registry statusCompleted

  • A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

    NCT00728390 · start 2008-12-15

    Registered record
    Registry ID
    NCT00728390
    Conditions
    Carcinoma, Non-Small Cell; Neoplasm Metastasis
    Interventions
    PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-12-15
    Completion
    2013-01-29
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small Cell; Neoplasm Metastasis
    InterventionPF-00299804
    PhasePhase 1
    Registry statusCompleted

  • Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

    NCT00768664 · start 2008-11-04

    Registered record
    Registry ID
    NCT00768664
    Conditions
    Head and Neck Neoplasms
    Interventions
    PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11-04
    Completion
    2012-04-18
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms
    InterventionPF-00299804
    PhasePhase 2
    Registry statusCompleted